View Older Stories View More Recent Stories

Jun 5, 2016 01:43PM New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair Show Durable Responses Across a Range of Cancers
Jun 5, 2016 08:00AM New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose Ipilimumab in Advanced Melanoma Presented at 2016 ASCO Annual Meeting
Jun 4, 2016 08:00AM New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival Data, To Be Presented at 2016 ASCO Annual Meeting
Jun 4, 2016 08:00AM New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung Cancer Demonstrate Response Rates Ranging from 48 to 71 Percent
Jun 1, 2016 05:00PM Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting
May 27, 2016 07:47AM Merck (MRK) Announces Positive CHMP Opinion for ZEPATIER
May 27, 2016 07:46AM Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union
May 24, 2016 02:35PM Merck Announces Third-Quarter 2016 Dividend
May 24, 2016 08:00AM Merck to Present at the UBS Global Healthcare Conference
May 18, 2016 05:20PM Merck (MRK) Plans KEYTRUDA, KEYNOTE-006 and KEYNOTE-001 Presentations at ASCO 2016
May 18, 2016 05:19PM New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting
May 16, 2016 08:02AM Merck (MRK) Will Present New KEYTRUDA Data in Head and Neck Cancer, NSCLC
May 16, 2016 08:00AM New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated Overall Survival Data in Non-Small Cell Lung Cancer As Well As Updated
May 12, 2016 08:32AM Merck (MRK) Will Present JANUVIA, Diabetes Pipeline, Other Data at 76th Scientific Sessions of the ADA
May 12, 2016 08:30AM Merck to Present Phase 3 Data on Investigational Medicines Ertugliflozin and MK-1293 at the 76th Scientific Sessions of the American Diabetes Association
May 5, 2016 06:45AM Merck Announces First-Quarter 2016 Financial Results
May 4, 2016 08:00AM Merck to Present at the Deutsche Bank 41st Annual Health Care Conference
Apr 28, 2016 08:00AM Christina Applegate and Merck Urge Insomnia Sufferers to Learn "Why They're So Awake"
Apr 27, 2016 08:00AM Merck, the American Diabetes Association and America's Diabetes Challenge Celebrity Voices Unite to Take on National Health Epidemic
Apr 26, 2016 11:39AM Journal of the American Medical Association Publishes Phase III Data from Allergic Asthma Trial with ALK's House Dust Mite SLIT-tablet, ACARIZAX®
Apr 19, 2016 05:01PM Merck (MRK) Animal Health Enters Agreement to Acquire Whisper Veterinary Stethoscope System
Apr 19, 2016 05:00PM Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System
Apr 19, 2016 02:08PM Merck (MRK) Comments on Blueprint PD-L1 Assay Comparison Project; Encouraged by Findings
Apr 19, 2016 02:05PM Merck Statement on Blueprint Project Findings Presented at the American Association for Cancer Research 2016 Annual Meeting
Apr 18, 2016 08:05AM Merck (MRK) Receives FDA Breakthrough Therapy Designation for KEYTRUDA in cHL
Apr 18, 2016 08:00AM Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA® (pembrolizumab) in Classical Hodgkin Lymphoma (cHL)
Apr 18, 2016 06:51AM Merck (MRK) Preents Data from Two ZEPATIER Phase 3s; High SVR Demonstrated
Apr 16, 2016 01:00AM Merck Announces Results From Phase 3 Studies of ZEPATIER™ (Elbasvir and Grazoprevir) in Chronic Hepatitis C Patient Populations at The International Liver Congress™
Apr 14, 2016 06:22AM Merck (MRK) Announces Strong Data from C-EDGE Head-to-Head Study
Apr 14, 2016 01:00AM Merck’s ZEPATIER™ (Elbasvir and Grazoprevir) Showed Superiority on Efficacy and Safety Endpoints Compared to Sofosbuvir Plus Peginterferon and Ribavirin Treatment Regimen in Phase 3 Trial
Apr 13, 2016 07:01AM Merck (MRK) Announces FDA Acceptance of KEYTRUDA sBLA; Priority Review Granted
Apr 13, 2016 07:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Recurrent or Metastatic Head and Neck Cancer, and Grants Priority Review
Apr 8, 2016 08:00AM Merck to Hold First-Quarter 2016 Sales and Earnings Conference Call on May 5
Apr 7, 2016 08:00AM Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016
Apr 6, 2016 08:03AM Merck (MRK) Will Present New KEYTRUDA Data at AACR Annual Meeting
Apr 6, 2016 08:00AM Merck to Present New Data for KEYTRUDA® (pembrolizumab) at the American Association for Cancer Research 2016 Annual Meeting
Apr 5, 2016 08:22AM Pfizer (PFE), Merck (MRK) Treat First Patient in Avelumab Phase 3
Apr 5, 2016 08:03AM Advaxis (ADXS), Merck (MRK) Complete First Two Dose Escalations in KEYNOTE-046 Trial
Apr 5, 2016 08:00AM Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
Apr 1, 2016 08:00AM Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency
Mar 30, 2016 07:00AM Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016
Mar 9, 2016 04:00PM Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening Treatment Access for Veterans with Chronic Hepatitis C Infection
Mar 8, 2016 08:04AM Sanofi Pasteur (SNY) and Merck (MRK) to End Joint Vaccines Operations in Europe
Mar 8, 2016 08:00AM Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strateg
Mar 7, 2016 04:30PM Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire
Mar 7, 2016 08:10AM Merck (MRK) Annnounces FDA Acceptance of KEYTRUDA sBLA
Mar 7, 2016 08:00AM FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Mar 4, 2016 10:00AM Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa
Feb 23, 2016 01:30PM Merck Announces Second-Quarter 2016 Dividend
Feb 22, 2016 11:30AM Merck Puts Spotlight on Women's Health and Well-being
View More Recent Stories View Older Stories